CDC recommends 2026–2027 COVID vaccines for all adults

Updated guidance recommends vaccination for adults aged 18 years and older, with pediatric recommendations based on immune status.

By
Teraya Smith
October 9, 2026
3 min

MDSpire News

Overview

CDC guidance updated October 8 recommends a 2026–2027 COVID-19 vaccine for all adults aged 18 years and older, regardless of prior vaccination or infection. Recommendations for children aged 6 months through 17 years depend on immune status, with vaccination recommended for those who are moderately or severely immunocompromised and shared clinical decision-making advised for other children.

Background

The CDC states that vaccine-derived and infection-acquired immunity decline over time and that updated vaccines are intended to improve protection against currently circulating SARS-CoV-2 strains. The agency identifies prevention of severe illness, hospitalization, and death as principal benefits of vaccination, and also lists reducing long COVID risk as a consideration. Guidance addresses timing after infection, product eligibility by age, and separate schedules for people who are moderately or severely immunocompromised.

Data Highlights

Population or product	2026–2027 guidance in source
Adults aged 18 years and older	Vaccination recommended regardless of previous vaccination or SARS-CoV-2 infection
Children aged 6 months through 17 years who are moderately or severely immunocompromised	Vaccination recommended
Other children aged 6 months through 17 years	Vaccination recommended through shared clinical decision-making
After COVID-19	Vaccination may be delayed for 3 months after symptom onset or, if asymptomatic, after a positive test
Spikevax (Moderna)	Available from age 6 months
Comirnaty (Pfizer-BioNTech)	Available from age 5 years
mNexspike (Moderna) and Nuvaxovid (Novavax)	Available from age 12 years

Key Findings

CDC recommends 2026–2027 COVID-19 vaccination for all adults aged 18 years and older, with emphasis on adults aged 65 years and older, people at increased risk of severe COVID-19, long-term care facility residents, people never vaccinated, and people with a history of long COVID.
For children aged 6 months through 17 years, vaccination is recommended for those who are moderately or severely immunocompromised; for other children, the recommendation is based on shared clinical decision-making.
After infection, vaccination may be delayed for 3 months from symptom onset or, for asymptomatic infection, from the positive test. CDC notes that reinfection risk is lower during the weeks to months after infection; earlier vaccination may be appropriate based on individual and local risk factors.
The four listed products have different minimum ages: Spikevax from 6 months, Comirnaty from 5 years, and mNexspike and Nuvaxovid from 12 years. CDC states that no product is preferred when multiple products are recommended for a patient's age group.
CDC directs clinicians to distinct schedules for people who are moderately or severely immunocompromised.
For the 2026–2027 formulation, FDA advised manufacturers to produce a monovalent JN.1-lineage XFG-targeted vaccine for use beginning fall 2026, following a May 28, 2026 VRBPAC recommendation, according to the supplied web research context.

Clinical Implications

When applying the guidance, clinicians should consider age, immune status, prior infection and vaccination, and the patient's risk of severe disease; product eligibility varies by age. For patients recently infected, the CDC permits a 3-month delay while noting that earlier vaccination may be appropriate in light of individual risk, close-contact risk, and local COVID-19 activity.

Conclusion

The CDC's 2026–2027 guidance recommends vaccination for all adults and uses immune status and shared clinical decision-making to guide recommendations for children. It also specifies post-infection timing, age-based product eligibility, and separate schedules for immunocompromised individuals.